Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of pyrotinib for HER2-positive advanced breast cancer
ChiCTR1900023152Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Nanchang
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by The Third Hospital of Nanchang. Primary endpoint: Progression-free survival. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900023152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023152.